New Study Using GlycoCheck Reveals Positive Effects of High-Intensity Interval Exercise on the Microvascular Glycocalyx


CHATTANOOGA, TENNESSEE, USA, August 16, 2022 – GlycoCheck, a medical testing device, distributed by Microvascular Health Solutions and marketed by NuLife Sciences, both BioRegenx subsidiaries, was used in a new peer-reviewed study. Published by the American Journal of Physiology and authored by researchers at the University Hospital Muenster, Germany, the study, Effects of high-intensity interval training on microvascular glycocalyx and associated microRNAs, evaluated how high-intensity interval training (HIIT) affects the microvasculature including the endothelial glycocalyx.

The study found the effects of physical fitness and exercise on microvascular parameters including glycocalyx thickness and associated miRNAs in young healthy adults. Researchers found that maximal exercise capacity was positively associated with microvascular glycocalyx thickness at baseline. Moreover, glycocalyx thickness increased with the improvement in exercise capacity postintervention, and the increase in glycocalyx thickness was predicted by acute elevation of miRNA-143 levels. Furthermore, glycocalyx thickness and number of perfused vessels changed in accordance with exercise performance after a 4-wk HIIT program. Researchers of the study conclude that HIIT may be performed to induce microvascular changes and increase glycocalyx thickness.

“This paper reinforces the need for people to engage in a regular exercise regimen to promote good health,” said Robert M. Long, Director of Product Development at NuLife Sciences, and Chairman of the Board of BioRegenx. Long continues, “Combining exercise with Endocalyx Pro™, a nutraceutical distributed by NuLife Sceinces, is shown in studies to improve microvascular health, and can be especially impactful for athletes or anyone of any age who wants to improve their body’s performance.”

Dr. Hans Vink, Chief Science Officer at NuLife Sciences and BioRegenx, is of the world’s leading researchers of endothelial glycocalyx health and says, “As someone who runs for exercise and who has a high MicroVascular Health Score™, this study offers substantiation that high-intensity cardio training improves the robustness of the glycocalyx.” Dr. Vink is the inventor of the GlycoCheck medical testing device and co-founder of GlycoCheck.

About NuLife Sciences
NuLife Sciences, Inc., ( is a research development, marketing and distribution company whose mission is to harness advanced technologies to redefine health and longevity from the inside out. We achieve this by increasing understanding of the biology that controls lifespan and anti-aging in the human body. We represent best in class products that enable people to lead longer and healthier lives. NuLife Sciences is wholly owned subsidiary of parent company, BioRegenx (, a holding company.

About BioRegenx
BioRegenx, Inc., ( a holding company, is the parent company of three wholly owned subsidiaries, Microvascular Health Solutions, Inc., My Body Rx, Inc., and NuLife Sciences, Inc. BioRegenx and its subsidiaries combine the patented intellectual property of the breakthrough GlycoCheck™ medical testing device, the patented nutraceutical Endocalyx Pro™, additional synergistic dietary supplement products sold under the My Body Rx brand, and a customer base of medical professionals and brand partners throughout North America.

Safe Harbor
This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements regarding potential sales, the success of the company’s business, as well as statements that include the word believe or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of BioRegenx, Inc., or its subsidiaries, to differ materially from those implied or expressed by such forward-looking statements. This press release speaks as of the date first set forth above, and BioRegenx, Inc., or its subsidiaries, assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, timely development of products, inability to deliver products when ordered, inability of potential customers to pay for ordered products, and political and economic risks inherent in international

Robert Doran
NuLife Sciences
+1 800-398-9842
email us here
Visit us on social media: